Let us dispose of the lazy version of this argument first. “Made in China” is not the problem. A very large share of the world’s legitimate active pharmaceutical ingredient is manufactured in China and India, in facilities that are registered with the FDA, inspected by it, and supplying drugs Americans take every day without incident.
The distinction that matters is not geography. It is whether the material moved through a regulated supply chain or around one — and both of those routes can start in the same industrial park.
Two supply chains, same origin
Route A — the regulated one. An API manufacturer registers its establishment with the FDA and is subject to inspection. It maintains a Drug Master File describing its process and controls. It sells to a US customer — a manufacturer or an outsourcing facility — under a quality agreement, with batch records, specifications, change control and stability data behind each lot. The import entry is declared for what it is. If something goes wrong, there is a named accountable party and a recall mechanism.
Route B — the other one. A chemical exporter lists the same compound on a trading platform. It sells in kilogram quantities to whoever wires payment, ships by international courier, and supplies a certificate of analysis as a PDF. The entry is often declared as a chemical or a sample rather than a drug. If something goes wrong, there is an email address.
Same molecule on the invoice. Entirely different products, because a drug is not just its chemical formula — it is the formula plus the evidence that this batch is what the label says.
What CGMP actually buys you
“CGMP” gets used as a marketing word, so it is worth naming what the framework requires:
- Registration and inspection. Establishments producing drugs for the US market register with the FDA and are subject to inspection, foreign facilities included.
- Validated processes. Not “it worked last time” — documented evidence that the process reliably produces material meeting specification.
- Tested, released batches. Each lot tested against defined specifications by defined methods, with a quality unit independent of production signing the release.
- Change control. A supplier cannot quietly switch a solvent, a resin or a subcontractor.
- Traceability and recall. Batch genealogy that allows a specific lot to be found and pulled.
- Stability data. An expiry date supported by evidence rather than by convention.
Every one of those costs money, which is the entire explanation for the price gap that makes gray-market material so attractive.
The border is a real control, and it has two relevant instruments
Operators tend to imagine customs as a lottery. It is closer to a filter with published rules.
Import Alert 66-40 authorises detention without physical examination of drugs from foreign establishments found not to be operating in conformity with CGMP. Firms appear on a Red List. To clear a detained entry, the responsible party has to demonstrate to the FDA that the violations were corrected; to come off the list, the firm has to show the underlying conditions are resolved.
Import Alert 66-41 covers detention without physical examination of unapproved new drugs promoted in the US, charged under section 801(a)(3) with reference to sections 505(a) and 201(p). It reaches products across categories, including articles labelled as supplements or cosmetics that carry disease claims. It was revised in 2026 and remains active.
Two consequences people miss. First, detention without physical examination means the burden flips: the shipment is held and you have to prove admissibility. Second, the importer of record is liable — and if you told a freight forwarder to put your business on that line, that is you.
Diligence you can run yourself, today, for free
Before wiring anything:
- Ask for the FEI number — the FDA Establishment Identifier for the manufacturing site. A registered facility knows it immediately. Hesitation is the answer.
- Check registration. The FDA publishes registered drug establishments. Confirm the site named on the certificate is the site that is registered, not a trading company in another city.
- Check the inspection history and the warning letter database for that firm and site.
- Check the import alert Red Lists for the firm.
- Ask whether a Drug Master File exists and whether you may be granted a letter of authorisation to reference it.
- Ask who the US agent is. A foreign establishment must have one. If nobody can name a person in the US, you are the accountable party by default.
A supplier operating in Route A finds these questions boring and answers them in a day. A supplier operating in Route B changes the subject to price, purity or how many clinics they already serve.
The certificate of analysis question
A certificate is only as good as the laboratory behind it and the batch it describes. Read for:
- a batch or lot number that matches the vials in front of you;
- named test methods, not just results;
- a manufacture date and retest or expiry date;
- an identifiable testing laboratory and signatory;
- net peptide content, not purity alone — see how peptides are actually made;
- endotoxin and sterility results if the material is destined for injection.
A certificate identical across every batch is not a test result. It is a template, and it is the most common single red flag in this market.
The part that is not about quality at all
Even a flawless, fully CGMP, FDA-registered Chinese API does not answer the regulatory question. Legality turns on whether the substance has a lawful pathway for your intended use — a bulks list entry, a USP monograph, or status as a component of an approved drug — and on who is permitted to compound with it. Excellent manufacture of a substance with no pathway produces a high-quality unapproved drug.
Both questions have to be answered. Operators usually answer neither and assume both. See the statutory map.
How to decide
| Signal | Regulated supply | Gray market |
|---|---|---|
| Buyer | Licensed pharmacy or manufacturer | Anyone who pays |
| Facility registration | FEI provided on request | Question deflected |
| Documentation | Batch-specific, method-referenced | One PDF, reused |
| Quality agreement | Signed, with change control | None offered |
| Payment | Invoice, commercial terms | Crypto or wire to a third party |
| Import entry | Declared as a drug | Declared as a chemical or sample |
| When something fails | Recall, investigation, accountable party | The account stops replying |
Where MDside sits
The practices we support do not buy API. They source finished preparations through licensed pharmacies whose specific authority we confirm in writing, which puts the manufacturing question inside a regulated relationship where it belongs. Where a substance has no completed pathway, it does not go on the formulary — however good the supplier’s paperwork is.
See how our peptide programs are structured, or read the supplier document pack.
Related reading
Frequently asked questions
Is Chinese peptide API illegal?
No. Country of origin does not determine legality. What matters is whether the manufacturing establishment is registered with the FDA and operating under CGMP, whether the import entry is lawful, and whether the substance itself has a lawful pathway for the intended use.
How do I check whether a foreign peptide supplier is FDA registered?
Ask for the site’s FDA Establishment Identifier and confirm it against the FDA’s published registered drug establishments, then check the inspection and warning letter databases and the import alert Red Lists for that firm.
What is Import Alert 66-41?
It authorises detention without physical examination of unapproved new drugs promoted in the United States, charged under section 801(a)(3) with reference to sections 505(a) and 201(p). Detained goods are held until the importer demonstrates admissibility.
Why is imported peptide so much cheaper?
Because the price difference is the compliance infrastructure: process validation, batch testing, an independent quality unit, change control, stability programmes, traceability and inspection readiness. Removing those removes most of the cost.
If my supplier sends a certificate of analysis, is that enough?
No. A certificate is only meaningful if it is batch-specific, references named methods, carries dates and an identifiable laboratory, and covers the attributes that matter for the route of administration. An identical certificate across every batch is a template.
General information about drug importation and manufacturing quality, not legal or customs advice. Import alert contents change; verify the current published version and consult counsel or a licensed customs broker before importing anything.